… markers, clinical trial end points and the understanding of pathogenesis of idiopathic
pulmonary fibrosis. We outline a practical approach to the treatment of these three patient groups. …

… of interferon γ-1b on survival in patients with idiopathic pulmonary fibrosis); n = 822). Comparison
of … trial of interferon-γ1b for idiopathic pulmonary fibrosis. Chest 2005; 127: 171–177. …

… Forced vital capacity (FVC) is a key measure of disease severity in patients with idiopathic
pulmonary fibrosis (IPF) and is an important clinical trial endpoint. We hypothesize that …

… Idiopathic pulmonary fibrosis is the most common diffuse interstitial … Currently, some,
such as interferon γ1b, pirfenidone, N-acetylcysteine, and bosentan, are in clinical trials.Therefore, …

… We did a pooled cohort study of 517 patients with idiopathic pulmonary fibrosis from three
… of efficacy end points in a controlled trial of interferon-γ1b for idiopathic pulmonary fibrosis. …

… for the management of idiopathic pulmonary fibrosis; these … the rate of progression of the
fibrosis process 37,38 measured … influence treatment efficacy, adherence to treatment certainly …

… The source population included all randomised subjects from a clinical trial of interferon
γ1b … GIPF-007: clinical trial of interferon γ1b in idiopathic pulmonary fibrosis (IPF); PIPF-004/-006…

… effect, this paper represents a landmark in the treatment of IPF. For the first time, primary end
… III study of interferon-γ1b, a compound that had previously shown promise as a treatment for …

… Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone:
results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 1999;159:1061-1069 …

… 4-yr survival in relation to the magnitude of serial change in forced vital capacity at 6 months
in patients with idiopathic pulmonary fibrosis (n = 84). Declines of 5–10% (marginal; ▾) and …